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Abstract
Background: Phenotypic changes during cancer progression are associated with alterations in gene expression,
which can be exploited to build molecular signatures for tumor stage identification and prognosis. However, it is
not yet known whether the relative abundance of transcript isoforms may be informative for clinical stage and
survival.
Methods: Using information theory and machine learning methods, we integrated RNA sequencing and clinical
data from The Cancer Genome Atlas project to perform the first systematic analysis of the prognostic potential of
transcript isoforms in 12 solid tumors to build new signatures for stage and prognosis. This study was also performed
in breast tumors according to estrogen receptor (ER) status and melanoma tumors with proliferative and invasive
phenotypes.
Results: Transcript isoform signatures accurately separate early from late-stage groups and metastatic from
non-metastatic tumors, and are predictive of the survival of patients with undetermined lymph node invasion
or metastatic status. These signatures show similar, and sometimes better, accuracies compared with known
gene expression signatures in retrospective data and are largely independent of gene expression changes.
Furthermore, we show frequent transcript isoform changes in breast tumors according to ER status, and in
melanoma tumors according to the invasive or proliferative phenotype, and derive accurate predictive models
of stage and survival within each patient subgroup.
Conclusions: Our analyses reveal new signatures based on transcript isoform abundances that characterize
tumor phenotypes and their progression independently of gene expression. Transcript isoform signatures
appear especially relevant to determine lymph node invasion and metastasis and may potentially contribute
towards current strategies of precision cancer medicine.
Background
Tumors advance through stages that are generally
characterized by their size and spread to lymph nodes
and other parts of the body [1]. Establishing the stage
of a tumor is critical to determine patient prognosis
and to select the appropriate therapeutic strategy [2].
Even though stage is generally defined from a number
of tests carried out on a patient, this information may
sometimes be incomplete or inconclusive. Advances
in the molecular characterization of tumors have led
to improvements in stage classification and clinical
management of patients [3]. Although tumors origin-
ate primarily from genetic lesions, their progression
involves other molecular transformations, which are
related to the activation of specific aggressive pheno-
types, like tumor spread and metastasis, and are often
reflected in gene expression changes [4, 5]. Accord-
ingly, the development of gene expression signatures
has been instrumental to complement and improve
stage identification and prognosis [6–9]. On the other
hand, gene expression summarizes the output of RNA
transcripts from a gene locus, which is mostly ex-
plained by one transcript isoform [10]. Furthermore,
we described before how solid tumors present fre-
quent changes in the relative abundances of isoforms
in comparison to normal tissues [11]. This prompts
the question of whether transcript isoform changes,
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which remain largely unexplored as predictive signatures
of tumor stage and survival, could hold relevant novel
mechanisms of tumor progression. We investigated the
potential of the relative abundances of transcript isoforms
to determine tumor staging and clinical outcome in 12
different tumor types, integrating RNA sequencing (RNA-
seq) and clinical annotation data for 12 tumor types from
The Cancer Genome Atlas (TCGA) project. Our analyses
revealed new signatures that characterize tumor pheno-
types and their progression that are largely independent of
gene expression. Knowledge about the relative abundance
of transcript isoforms in tumors can potentially help pre-
dicting stage and clinical outcome and contribute towards
current molecular strategies in precision cancer medicine.
Results
Relative abundances of transcript isoforms are predictive
of tumor stage
We considered the standard clinical annotation for
tumors based on the tumor size (T), lymph-node
involvement (N), metastatic status (M), and combined
stage (S) for 4339 patient samples from 12 different
tumor types from TCGA (Additional file 1). For each
tumor type, we considered the comparison of the tran-
scriptomes between groups of samples in early and
late-stage groups according to each stage class inde-
pendently. That is, for metastasis, we compared non-
metastatic samples (M0) against metastatic ones (M1),
whereas for the tumor size (T), lymph-node involve-
ment (N), and stage (S) annotations, we compared early
and late stages (groups described in Table 1) (see
“Methods”). We first calculated the set of transcripts
whose relative abundance, measured as percent spliced
in (PSI) values, present the best discriminant potential
between these groups by using information-based mea-
sures with a subsampling strategy to ensure balanced
comparisons (Fig. 1a and Additional file 2: Figure S1a).
Additionally, we considered only those transcripts that
on average change PSI more than 10 % between groups,
i.e. |ΔPSI| > 0.1 (see “Methods”). These produced a vari-
able number of transcript isoforms per tumor type and
clinical annotation that discriminate between early and
late stages or between M0 and M1 (Additional file 3).
To characterize the functional involvement of the
found discriminant isoforms, we performed an enrich-
ment analysis of cancer hallmarks (see “Methods”)
(Additional file 4). Testing discriminant isoforms for
each stage class and tumor type independently yielded
frequent enrichment of MYC targets, oxidative phos-
phorylation, mTORC signaling, DNA repair, and Inter-
feron response (Additional file 2: Figure S1b). Notably,
aggregating all tumor types for each clinical class, the
discriminant transcripts show enrichment in MYC
targets and genes involved in oxidative phosphorylation
(Fig. 1b). On the other hand, combining discriminant
isoforms from different clinical classes in the same
tumor type, only five of the 12 tumor types tested show
enriched hallmarks (Fig. 1c), which include the enrich-
ment of MYC targets in skin cutaneous melanoma
(SKCM) and kidney papillary carcinoma (KIRP). These
results indicate that there are frequent transcripts iso-
form changes in cancer-relevant pathways during
tumor progression, many of which may be driven by
MYC activity. To test some of our findings, we com-
pared the ΔPSI values of the discriminant transcripts
for metastasis in SKCM with the ΔPSI values measured
Table 1 Number of samples analyzed for each tumor type and stage
T N M S
Tumor type Acronym Early Late Early Late Early Late Early Late
Breast invasive carcinoma BRCA 256 (T1) 147 (T3, T4) 455 (N0) 171 (N2, N3) 836 (M0) 15 (M1) 164 (S1) 15 (S4)
Colon adenocarcinoma COAD 45 (T1, T2) 31 (T4) 149 (N0) 39 (N2) 179 (M0) 33 (M1) 40 (S1) 34 (S4)
Head and neck squamous cell carcinoma HNSC 35 (T1) 110 (T4) 166 (N0) 166 (N2, N3) 77 (S1, S2) 169 (S4)
Kidney chromophobe KICH 20 (T1) 19 (T3, T4) 20 (S1) 19 (S3, S4)
Kidney renal clear cell carcinoma KIRC 245 (T1) 186 (T3, T4) 233 (N0) 16 (N1) 419 (M0) 77 (M1) 240 (S1) 78 (S4)
Kidney renal papillary carcinoma KIRP 71 (T1) 38 (T3, T4) 23 (N0) 16 (N1, N2) 66 (S1) 38 (S3, S4)
Lung squamous cell carcinoma LUSC 93 (T1) 59 (T3, T4) 242 (N0) 37 (N2, N3) 195 (S1) 76 (S3, S4)
Lung adenocarcinoma LUAD 137 (T1) 57 (T3, T4) 281 (N0) 70 (N2, N3) 307 (M0) 22 (M1) 99 (S1) 242 (S3, S4)
Ovarian serous cystadenocarcinoma OV 18 (S2) 243 (S4)
Prostate adenocarcinoma PRAD 69 (T2) 93 (T3, T4) 129 (N0) 14 (N1)
Skin cutaneous melanoma SKCM 68 (M0) 17 (M1)
Thyroid carcinoma THCA 137 (T1) 179 (T3, T4) 220 (N0) 211 (N1) 270 (S1) 48 (S4)
The number of samples used for the comparison early versus late are indicated for each annotation T, N, M, S. Stages I, II, III, and IV are indicated as S1, S2, S3,
and S4, respectively. Comparisons were performed between the earliest and latest available stage groups, with some exceptions for which adjacent stages were
added to have enough samples for comparison. Empty cells correspond to cases not tested due to lack of sufficient samples or complete lack of annotation in
the samples
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between metastatic (SKMel147) [12] and non-metastatic
(Mel505) [13] melanoma cells (see “Methods”). Of the 958
discriminant isoforms in SKCM, 817 had expression in
the cell lines. From these, 504 (61.7 %) show a change
in PSI in the same direction and 253 of them have
|ΔPSI| > 0.1 in both comparisons (Additional file 2:
Figure S1c).
To build signatures of tumor stage based on transcript
isoforms, we applied a multivariate feature selection
method on the discriminant isoforms selected before to
obtain a non-redundant subset of predictive transcripts,
which we used to build logistic model trees (LMT) for
each tumor type and stage class (Fig. 1a) (models given
in Additional file 5). Each one of these models represents
a transcript signature for each stage class and each tumor
type. Using cross-validation on the annotated TCGA
samples, the mean accuracy of the models in terms of the
area under the ROC curve (AUC) is 0.783 (Fig. 1d),
with similar average precision-recall values (Additional
file 2: Figure S1d). T-models show the best accuracies
(mean AUC = 0.824), with the models for KIRP, kidney
























Fig. 1 a Workflow to obtain discriminant transcript isoforms and predictive models. Given two patient groups, we subsampled two equal sized
subsets, one from each group (e.g. metastatic and non-metastatic), which were compared using information-based measures, denoted as Iiso. At
each iteration step, the group labels were randomized to obtain an expected measure, denoted as Irand. After 100 iterations, two distributions
were produced for each isoform corresponding to observed (Iiso) and expected (Irand) values. Transcript isoforms with a difference of mean PSI values
>0.1 in absolute value between the two patient groups and with a positive difference of the means of the observed and expected distributions for all
information-based measures used were then considered as discriminant, which were then used to evaluate enriched cancer hallmarks. Discriminant
isoforms were further filtered for redundancy with a Correlation Feature Selection strategy to build a predictive model, which was evaluated using
cross-fold validation (see “Methods”). b Enriched hallmarks in the set of discriminant isoforms for each stage class, metastasis (M), tumor size
(T), lymph-node involvement (N), and overall staging (S), using all isoforms selected across all tumor types. c Enriched hallmarks for each tumor
type using all discriminant isoforms selected across all stage classes in each tumor type independently. d Accuracies of the classifiers for each
tumor type for the T, N, M, and S annotation, given as the distributions of the areas under the receiving operating characteristic (ROC) curves
(AUC). The variation on each bar indicates the minimum and maximum AUC values. Some models are absent due to lack of sufficient samples
(Table 1). e PSI distributions for the transcript isoforms of IDO1 in PRAD, SYK in SKCM, and GAS7 in OV, for the N-, M-, and S-models, respectively
(Wilcoxon test p values <0.001)
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and neck squamous cell carcinoma (HNSC) being the
most accurate (mean AUC >0.87).
The KIRP T-model includes an isoform for PAX6.
Increased inclusion of exon 5 of this gene has been
related to neuronal differentiation [14], which we see
associated with the late T stage (Additional file 2: Figure
S2a). The best N-models correspond to KIRP and pros-
tate adenocarcinoma (PRAD) (mean AUC >0.89). The
KIRP N-model includes an isoform in the MAP kinase
MKNK1 (Additional file 2: Figure S2a), suggesting a
similar involvement in cancer as MKNK2 [15]. The
PRAD N-model (mean AUC = 0.986) includes an iso-
form of IDO1 (Fig. 1e), a gene related to anti-tumor
defense [16]. The best M-model corresponds to SKCM
(mean AUC = 0.93) and includes an isoform change in
the transmembrane gene TM6SF1 (Additional file 2:
Figure S2a) and the tyrosine kinase SYK (Fig. 1e). In
metastatic melanoma samples, SYK shows an increase in
the abundance of the long form and a decrease of the
short form, as previously observed in breast tumors [17].
Finally, the best S-models correspond to COAD, breast
invasive carcinoma (BRCA), KICH, and ovarian serous
cystadenocarcinoma (OV) (AUC >0.9). Interestingly, OV
S-model includes an isoform in the cancer driver GAS7
(Fig. 1e). In general, we found no overlap between the
different stage models. A notable exception is an isoform
of NSUN7 that appears in all models for kidney renal
clear cell carcinoma (KIRC) with high PSI values at
late-stage and an isoform of SKA3 that appears in the
N-, T-, and S-models for KIRP, with low PSI values at
late stages. The low general overlap is consistent with
pathological transformations being associated with
multiple molecular alterations.
Transcript isoform changes are predictive of survival in
patients with unknown stage
We hypothesized that if the derived transcript signatures
provide clinically relevant information, we should find
worse clinical outcomes for patients predicted to be at a
late stage. We thus performed a blind test on those
samples that lacked stage annotation, and therefore were
not used for building the models, to predict the tumor
stage using the model for the corresponding tumor type
(Fig. 2a and Additional file 1). Additionally, we only per-
formed the blind test in those tumor types for which late
clinical stage was significantly associated with a worse
prognosis in the labeled samples (Table 2). There were
40 samples from COAD, 116 from lung adenocarcinoma
(LUAD), and 80 from BRCA that lacked M annotation.
After prediction with the M-model from each tumor
type, we obtained a total of 226 patients predicted as M0
and 10 patients predicted as M1. Aggregating patients
according to the predicted metastatic class yielded a
significant difference in survival between the two groups
(p value = 0.0079) (Fig. 2c). Regarding lymph node inva-
sion, there was one sample from COAD, 10 from LUAD,
82 from KIRP, 247 from KIRC, and 74 from HNSC with-
out N annotation. After predicting with the N-models
from the corresponding tumor types, 356 and 58 pa-
tients were predicted as early and late N, respectively.
Survival analysis with the aggregated patients yielded a
significant difference between the two predicted groups
(p value = 0.013) (Fig. 2d). Finally, for the S stage, we
predicted on a set of 91 samples without S annotation
(eight from COAD, 18 from BRCA, 47 from HNSC, 11
from KIRP, four from lung squamous cell carcinoma
(LUSC), two from thyroid carcinoma (THCA), and one
from LUAD). This resulted in 47 and 44 samples
predicted as early and late, respectively, which showed
no difference in survival (p value = 0.479). These results
represent an independent validation of our transcript
signatures and provide evidence that the relative abun-
dances of transcripts may hold some predictive value
for tumor staging and prognosis.
No relation of isoform signatures with stromal and
immune cell content
To assess whether the purity of the samples could be a
potential confounding factor of the derived signatures,
we tested the correlation between the transcript PSI
values of our models against signatures of stromal and
immune cell content [18] (see “Methods”). Overall, all
signatures showed low correlation with stromal content
(mean Pearson |R| <0.4), and all except the N-model in
BRCA (Pearson R = 0.433) had mean |R| <0.4 with im-
mune cell content (Additional file 6). From the 547 tran-
script isoforms tested, 95 % show a correlation |R| <0.4
(Pearson) for both stromal and immune scores. Among
the few cases with |R| >0.5 there is an isoform of ENAH
(Additional file 2: Figure S2d), which is present in the T-
models in KIRP and COAD and that was previously
linked to an invasive phenotype [19]. Recent analyses
have shown that clinical stage does not correlate with
tumor purity in the TCGA samples [20]. Our analysis
further supports those results and indicates that
isoform-based signatures of stage do not reflect stromal
or immune cell content.
No universal transcript isoform signature for tumor staging
Our results prompt the question of whether there
might be a universal signature of stage and survival
based on transcript isoform changes. To test this, we
grouped all annotated samples from the different tumor
types according to the stage class and applied the same
analyses as before. We could only build M- and S-
models due to the lack of common isoforms with discrim-
inant power for the other classes (Additional file 7). The
average AUC values for M- and S-models were lower than
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before, with mean AUC of 0.5 and 0.685, respectively. Ag-
gregating samples from BRCA, COAD, and LUAD, we ob-
served a slight increase in accuracy (mean AUC= 0.702).
Similarly, analyzing KIRC, KIRP, and KICH samples to-
gether, the S-model achieves mean AUC= 0.809. In this
case, approximately half of the isoforms were present in
the previous models. Finally, analyzing the squamous
tumors together (HNSC and LUSC), we derived N- and
S-models with mean AUC = 0.72. For other combinations,
we could not find accuracies greater than AUC = 0.5. This
indicates that despite some overlapping features across
tumor types, there is no common signature for all the
tested tumor types.
Transcript signatures provide better predictions than
event-based signatures in retrospective datasets
We tested whether local alternative splicing events, as
opposed to transcript isoform changes, could also de-
termine stage. We applied our analysis pipeline using
PSI values for all events in the same tumor samples
used before. For most of the stage classes we observed
similar or smaller accuracy values for events compared
to transcript models (average AUC 0.617 versus 0.778,
respectively) (Fig. 2d and Additional file 8). Only 23.5 % of
the isoforms in models overlap with at least one alter-
native splicing event from the event-based models:
16.51 % overlap with alternative 5′/3′ splice-sites,
a d
b c e
Fig. 2 a Illustration of the blind test on unlabeled patients. Patients without annotated stage were predicted using the model of the corresponding
tumor type, for each of the stage classes independently. Patients predicted as early or late were collected into two separate groups and tested for
differences in survival. This test was performed for each stage class independently and only using tumor types that showed an association between
stage and survival in the labeled patients (Table 2). b, c Survival (Kaplan–Meyer) plots associated with the test for M-models and N-models, respectively.
They indicate the survival percentage (y-axis) versus survival in months (x-axis) based on the predicted stage on the unannotated samples using the
classifier for each corresponding tumor type. The p value in each plot corresponds to the Cox regression between the two groups and HR indicates
the hazard ratio. d Accuracies of the transcript isoform models (I) compared to the gene (G) and event (E) models. Accuracies are given as boxplots for
the distribution of AUC values (y-axis) from a tenfold cross-validation for each tumor type (x-axis) for the M-, S-, N-, and T-models. Tumors for which
stage data were missing are not shown (Table 1). e Survival (Kaplan–Meyer) plot of the early and late-stage predictions performed with the gene-based
S-models on unannotated samples. The p value corresponds to the Cox regression between the two groups. HR hazard ratio
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mutually exclusive exons, retained introns, or cassette
exon events, and 6.54 % overlap with alternative first or
last exon events. Moreover, 82.39 % of isoforms in
models overlap with at least one of the pre-calculated
alternative splicing events. This indicates that a consid-
erable number of changes in exon-intron structures
described by the isoform models that are predictive of
tumor stage cannot be captured in terms of simple
alternative splicing events.
Transcript signatures provide relevant information about
tumor metastasis and lymph node invasion
independently of gene expression
Previously proposed molecular classifiers of stage were
based on gene expression [7, 8]. We thus tested the rela-
tion of our transcript signatures with gene expression.
We observed that the proportion of genes with differen-
tial expression (DE) vary markedly between transcript
signatures (Additional file 5 and “Methods”). For M-
models, nine (18 %) genes in the SKCM and four (18 %)
genes in KIRC showed DE. For N-models, we only found
three (14 %) in PRAD and 13 (68 %) in THCA. In
contrast, T-models presented frequent changes across
the different tumor types, with 17 (46 %) in KIRP, seven
(27 %) in KIRC, six (33 %) in LUAD, four (50 %) in
THCA, and one in HNSC (5 %). Similarly, S-models also
showed frequent DE: 16 (52 %) in KIRC, 12 (46 %) in
KIRP, one (25 %) in LUAD, and one (7 %) in BRCA.
Next, we compared the discriminative power of tran-
script and gene expression signatures. We thus applied
our pipeline to gene expression values to derive gene-
based signatures of stage (see “Methods”). The overall
accuracy for gene-based signatures was similar to
isoform-based models (average AUC values 0.783 and
0.781 for isoforms and genes, respectively) (Fig. 2d and
Additional file 9). Interestingly, isoforms had better
mean accuracies for the M-model in LUAD (0.883
versus 0.535) (Fig. 2d, upper left panel) and for the N-
model in PRAD (0.986 versus 0.839) (Fig. 2d, lower left
panel), compared to gene models. In contrast, the gene-
based S-model for THCA showed higher accuracy
(0.529 versus 0.836) (Fig. 2d, upper right panel). Gene
and isoform based models generally involved different
genes with only few exceptions, including CD72 in
SKCM M-models, PTGS2 and VIPR1 in the THCA T-
models, SLC14A1 in COAD S-models, and DNASE1L3
KICH S-models. Interestingly, gene-based S-models
were predictive of survival for samples lacking stage S
annotation (p value = 0.0024) (Fig. 2e), whereas no
significant difference in survival was found with the
gene-based M- and N-models (p values = 0.983 and
0.161, respectively).
The results described above suggest that genes and
transcripts provide independent information and may
yield better signatures when combined together. We
thus built mixed models of gene expression and tran-
script relative abundance. We started with all gene and
transcript discriminant features and selected a non-
redundant set of features to build logistic-model trees.
The accuracy of these mixed models was on average
better (mean AUC = 0.831) than using only transcripts
or genes (Additional file 2: Figure S3a). Notably, the
transcript signatures performed better than the mixed
signatures for the LUAD M-model (AUC = 0.883 versus
0.814) or the PRAD N-model (AUC = 0.986 versus
0.938). In contrast, the mixed model performed better in
the COAD M-model (AUC = 0.831 versus 0.864) and the
HNSC S-model (AUC = 0.676 versus 0.778). Addition-
ally, mixed models are able to predict survival differ-
ences between early and late stages for the N and S
stage classes (p value = 0.041 and 0.033, respectively)
(Additional file 3: Figure S3b and S3c).
Finally, we compared our transcript signatures with
an expression signature of 44 genes built to differen-
tiate metastatic and late-stage samples in colon
cancer [21] (see “Methods”). The mean AUC values
obtained for the metastatic annotation (M) and the
overall stage (S) were 0.612 and 0.649, respectively,
for the gene expression signature and 0.82 and 0.94
for our transcript signatures. Notably, none of the
genes involved in our transcript models for COAD
presented DE. Our analyses indicate that changes in
the relative abundance of transcripts hold relevant in-
formation about tumor transformation independently
of gene expression changes.
Table 2 Survival analysis between early and late-stage patient
groups
Tumor type T N M S
BRCA p = 0.375 p = 0.00012 p = 0.008 p = 0.0007
COAD p = 0.0011 p = 0.011 p = 1.48e-05 p = 0.012
HNSC p = 0.051 p = 0.0137 p = 2.49e-07
KICH p = 0.00896 p = 0.00896
KIRC p = 2e-15 p = 0.0125 p = 0 p = 0
KIRP p = 0.0043 p = 0.005 p = 8.86e-007
LUSC p = 0.029 p = 0.071 p = 0.025
LUAD p = 7.02e-09 p = 3.26e-06 p = 0.165 p = 7.02e-09
OV p = 0.0537
PRAD p = 0.456 p = 1
SKCM p = 0.418
THCA p = 0.324 p = 0.597 p = 2.49e-07
p values from the survival test comparing the patient subsets from Table 1.
The p values were obtained using a Cox proportional hazards regression
model. Empty cells correspond to cases not tested due to lack of sufficient
samples (see Table 1)
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Transcript relative abundances as prognostic markers in
ER-negative breast tumors
Molecular subtypes in cancer have implications for
prognosis and therapy that go beyond the staging
system [6, 22, 23]. In breast cancer, tumors that are
negative for the estrogen receptor (ER) have a generally
worse prognosis and gene expression signatures are
generally less accurate for ER-negative than for ER-
positive tumors [3, 7]. To test whether transcript-based
signatures could be relevant for ER-negative tumors, we
separated the samples according to the expression
ranking of the ER gene (ESR1) into the top (ER+) and
bottom (ER–) 25 % (237 samples each) (Fig. 3a). Inter-
estingly, applying our pipeline we identified 2591 dis-
criminant transcript isoforms between the ER+ and
ER– subgroups (Fig. 3b and Additional file 9). These
transcriptome changes were validated using RNA-seq
data from the knockdown of ESR1 and control in
MCF7 cells [24] (Additional file 2: Figure S4a and
“Methods”). We derived a predictive model with 81 dis-
criminant transcripts that separated ER+ and ER– sam-
ples with an average AUC of 0.999 (Fig. 3c). Among the
largest PSI changes, we found an isoform of the MAP
kinase MAP3K7, whose long isoform was linked before
to apoptosis [25], which we found to be less abundant
in ER– samples (Additional file 2: Figure S4b). Notably,
47 (58 %) of the genes with transcripts in this model
show DE, suggesting a link between ER expression and
the differential use of transcript isoforms.
The observed transcriptome differences between ER+
and ER– subtypes warrant a separation of these two sets
to build transcript signatures of stage. Accordingly, we
considered early and late-stage patients in each ER group
separately (Table 3). Since ER– samples show significant
differences in survival between early and late stages for










Fig. 3 a Ranking (x-axis) of breast tumor (BRCA) samples according to ESR1 expression (gene TPM) (y-axis). ER+ and ER– subsets were defined as
the top and bottom 25 % of the ranking, respectively, leaving out samples in the interquartile range (IQR). b Heat map of PSI values, from 0 (blue)
to 1 (yellow), for the top 35 isoforms that separate ER+ and ER– subsets. Isoforms are labeled by gene name (y-axis). Samples are clustered according
to the PSI values using Euclidean distance and Ward’s method. c Accuracies in terms of AUC values (y-axis) from a tenfold cross-validation for the
transcript isoform signatures for the comparison of ER+ and ER– samples, and for the comparison of early and late N, S, and T stages within ER+ or
ER– subsets. The variation on each bar indicates the minimum and maximum AUC values. d PSI distribution of the isoform in TNFRS8 that changes
between early and late S stage in ER– samples (Wilcoxon test p value = 0.1046). e Accuracies in terms of AUC values (y-axis) from a tenfold
cross-validation for the transcript isoform signatures (Iso-model) and the gene expression signatures OncotypeDX, MammaPrint, and PAM50,
indicated in grayscale. Each signature was tested to predict the separation of ER+ and ER– breast tumor samples or the separation between
early and late (N, S, and T) stage in ER+ or ER– separately. The variation on each bar indicates the minimum and maximum AUC values
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(Additional file 2: Figure S4c and S4d), we expect that a
signature for stage may be relevant for prognosis. In
contrast, ER+ samples do not show any significant
differences in survival. Using our feature selection
pipeline, we obtained 456 and 249 isoforms that best
discriminate between early and late stages in the ER–
and ER+ subsets, respectively (Additional file 9). The
isoforms for ER– show enrichment in various cancer
hallmarks, including DNA repair, apoptosis, and
epithelial-mesenchymal transition (Additional file 2:
Figure S4e). In contrast, there were no enriched hall-
marks associated with the isoforms in the ER+ subset.
Building stage signatures as before for ER+ and ER–
independently (Additional file 9), we obtained average
accuracies of AUC = 0.794 (ER–) and AUC = 0.756
(ER+) (Fig. 3c), with similar values for the precision-
recall (Additional file 2: Figure S4f ). Notably, none of
the derived signatures showed DE at the gene level.
Additionally, the ER– S-model includes TNFRS8
(Fig. 3d), a member of the tumor necrosis factor
receptor superfamily. Another member of this family,
TNFRSF17, was related before to prognosis in the
ER– samples [3]. Unlike for the previous models,
there were not enough unlabeled samples to perform
a blind test. Taken together, these results show that
transcript variants can be informative for stage and
prognosis in ER-negative tumors.
We further compared our transcript signatures with
known gene expression signatures for breast tumors:
OncotypeDX [26]; MammaPrint [27]; and PAM50 [28]
(see “Methods”). Although these signatures were not
originally designed to identify tumor stage, they bear
predictive value for this purpose [7]. Their accuracies
to separate the ER+ and ER– subgroups were very
similar to our transcript signatures (Fig. 3e). This is
expected for PAM50 and OncotypeDX, as they include
ESR1. We then tested how well the gene signatures
differentiate stage within each subset, ER+ or ER–,
independently. In general, PAM50 performed better
than the two other signatures, except for S in ER– and
for N in ER+, where MammaPrint performs better,
and for T in ER–, where OncotypeDX performs better
(Fig. 3e). Notably, in all cases the transcript signature
had better accuracies. We conclude that transcript
isoform models can provide relevant information to
determine stage and hence complement current clin-
ical signatures.
Transcript relative abundances characterize an invasive
phenotype and survival in melanoma
Clinical outcome of SKCM remains poor due to its high
degree of heterogeneity [29]. The microphthalmia-
associated transcription factor (MITF) presents highly
dynamic expression patterns in connection to prolifera-
tion and invasion in melanoma, with relevance for
prognosis and therapy [30, 31]. Overexpression and
downregulation of MITF have been connected to prolif-
erative and invasive phenotypes, respectively [32]. We
thus tested whether there are specific transcript signa-
tures linked to these phenotypes that could be linked to
survival. We pooled the top and bottom 25 % of melan-
oma samples according to MITF expression into the
MITF+ and MITF– sets, respectively (96 samples per
set) (Fig. 4a). Although these subsets do not show a
significant difference in survival, samples in the top and
bottom 10 % of MITF expression (36 samples per set)
show a significant difference, with MITF overexpressed
samples showing worse prognosis (p = 0.029) (Fig. 4b).
Our feature selection strategy (Fig. 1a) yielded 2387
discriminant isoforms between MITF+ and MITF–
(Fig. 4c and Additional file 9). We validated these
isoforms by comparing their ΔPSI values with those ob-
tained from the knockdown of MITF in melanoma cells
compared to controls [13] (Additional file 2: Figure S5a
and “Methods”). The found discriminant isoforms are
enriched for multiple cancer hallmarks, including EMT
and the mTOR pathway (Additional file 2: Figure S5b).
To further characterize their differences, we built a
model to separate MITF+ and MITF– samples with 72
isoforms, which showed a mean AUC of 0.996 (see
“Methods”). This model included a transcript isoform
for the cancer driver TPM1, which is highly included in
MITF+ and was linked before to tumor growth [33] (Add-
itional file 2: Figure S5c), as well as for RAB27A, a compo-
nent of the melanosome that is transcriptionally regulated
by MITF [34] and that is lowly included in MITF+ sam-
ples (Additional file 2: Figure S5d). From this signature, 37
(66 %) of the genes involved showed DE between MITF+
and MITF– subgroups, pointing to a link between MITF
expression and differential usage of transcript isoforms in
multiple genes.
To test whether the melanoma phenotypes are associ-
ated with different transcript transformations during
tumor progression, we studied the MITF+ and MITF–
sets independently to derive signatures of survival. We





Early Late Early Late Early Late
ER– 72 (T1) 48 (T3, T4) 122 (N0) 37 (N2, N3) 48 (S1) 55 (S3, S4)
ER+ 54 (T1) 29 (T3, T4) 130 (N0) 36 (N2, N3) 31 (S1) 43 (S3, S4)
The number of samples used for the early vs. late comparison is indicated for
each annotation T, N, and S. Stages I, II, III, and IV are indicated as S1, S2, S3,
and S4. In some cases, more than one clinical stage is included in a patient
group to have sufficient samples. Due to the insufficient number of annotated
samples, it was not possible to build M-models
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selected samples in the top and bottom 40 % according
to days of survival (36 samples per group) and used our
pipeline to calculate the isoforms that best separate
these groups within each phenotype. The discriminant
isoforms in the invasive phenotype (MITF–) were
enriched for multiple cancer hallmarks, whereas the
proliferative phenotype (MITF+) presented enrichment
only for activation of KRAS signaling, which does not
appear in the invasive phenotype (Additional file 2:
Figure S5b). We then built models of survival for each
subset independently using LMTs (Additional file 9).
Cross-validation yielded for MITF+ (34 isoforms) and
MITF– (46 isoforms) accuracies of AUC = 0.854 and
0.896, respectively (Fig. 4d and Additional file 2: Figure
S5e). Notably, the MITF– model includes a transcript
isoform for the MAP Kinase-Activating Death Domain
gene MADD (Fig. 4e), which does not change expres-
sion at the gene level. MADD is a cancer driver and it
was shown before that expression of isoforms that skip
exon 16 has anti-apoptotic effects [35]. Interestingly,
the PSI of the MADD isoform that skips exon 16 is
higher in the group with worse prognosis, suggesting
that the anti-apoptotic function of MADD is related to
worse prognosis in invasive melanoma. Taken together,
our results provide evidence of distinct transcript abun-
dance patterns linked to melanoma phenotypes and
survival.
Discussion
We described the first systematic analysis of the poten-
tial of transcript relative abundances to determine stage
and clinical outcome in multiple solid tumors. We de-
rived novel molecular signatures for 12 different tumor
types that can separate tumors according to clinical
stage or metastatic status in retrospective datasets.
Importantly, a blind test on patients with unknown
stage or metastatic status can separate patients accord-





Fig. 4 a Ranking (x-axis) of melanoma (SKCM) samples according to MITF expression (gene TPM) (y-axis). We indicate the top and bottom 10 %
and 25 % of the samples used for analyses. b Survival (Kaplan–Meyer) plot for the top and bottom 10 % of the samples according to the ranking
of MITF expression. The p value corresponds to the Cox regression between the two groups. HR hazard ratio. c Heat map of PSI values, from 0
(blue) to 1 (yellow), for the top 30 discriminant isoforms according to |ΔPSI| value between the MITF+ and MITF– subgroups. Isoforms are labeled
by gene name (y-axis). Samples are clustered according to the PSI values using Euclidean distance and Ward’s method. d Accuracy given in terms
of the distribution of AUC values (y-axis) from a tenfold cross-validation for (from left to right in the x-axis) the survival model for MITF+, MITF– as
well as for the separation between MITF+ and MITF– subgroups using 25 % (Q1 vs. Q4) or 10 % (D1 vs. D10) of the top and bottom samples in
the ranking of MITF expression. The bars show the minimum, mean, and maximum AUC values. e Distribution of PSI values for the isoform in
MADD that is predictive of prognosis in the MITF– subgroup (Wilcoxon test p value = 7.781e-05)
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better accuracies than local alternative splicing events
and can describe more complex changes in exon-intron
structures. Although a multi-cancer signature of clinical
outcome based on gene expression has been proposed
[36], our results argue against a generic transcript-
based signature for all tumors types. Rather, transcript
isoform changes appear linked to tumor-type specific
processes, with several of them related to MYC activity,
in concordance with recent findings [37].
We observed a widespread association between tran-
script isoform changes and expression changes in T- and
S-models across tumor types and around 60 % of the
genes with DE in all models correspond to KIRC and
KIRP, indicating that transcript and gene changes are
tightly coupled during progression of these tumors. In
contrast, this association is low or absent for most tumor
types for M- and N-models. The blind test showing that
patients with predicted metastasis or late N-stage have a
worse prognosis was for tumor types for which none of
these models show gene expression differences. The value
of the transcript signatures is further highlighted when
compared to known and newly derived gene expression
signatures or with mixed models combining gene expres-
sion and transcript abundances. These results indicate that
transcripts signatures provide information independent
from gene expression to describe tumor progression and
especially in metastasis and lymph node invasion.
We also extracted signatures for specific tumor subtypes
in breast cancer and melanoma. We reported many
significant transcript isoform changes between breast tu-
mors according to ER expression and between melanoma
samples according to MITF expression. Additionally, we
observed a widespread association between transcript iso-
form and expression changes in relation to ER expression
and according to MITF expression. An interesting possi-
bility is that the activity of these two transcription factor
genes could trigger expression and transcript isoform
changes in the same genes in these tumors, pointing to
new mechanisms of gene regulation worth investigating
further. We further derived transcript signatures of
stage independently in each sample subset that involved
different genes, thereby highlighting the relevance of
determining the transcriptome repertoire in tumor
samples to derive accurate molecular signatures of tumor
progression.
We observed partial reproducibility of the discrimin-
ant isoforms in experiments using cell lines. Transcrip-
tional differences between cell lines and tumor tissues
are thought to stem from the loss of the stromal and
immune components by cells in culture [38]. Our
analyses discard an association between the transcript
signatures and the composition of stromal and im-
mune cells in the tissue samples. It could be possible
that part of the signatures reflects the interaction of
tumor cells with their environment in tissues samples,
which would be undetectable in cell lines. Our results
support the notion that phenotypic states of tumor
cells, like invasiveness, may be reflected on the relative
abundance of transcript isoforms and may be partly
triggered by external cues, such as inflammation or
metabolic stress [39]. On the other hand, the observed
commonalities between tumor cells and tissues suggest
that some of these alterations could be investigated
further using cell lines.
The clinical validity of our findings remains to be
tested. Our cross-fold validation in retrospective datasets
shows good accuracies in general for transcript signa-
tures and, in particular, isoform-based M- and N-models
are generally more accurate compared to gene expres-
sion models on the same datasets. Additionally, we have
shown that predicted metastatic and late lymph-node in-
volvement in non-annotated patients is associated with
worse prognosis. These results thus suggest that isoform
models may be potentially useful to indicate metastasis
or lymph node invasion. To conclusively establish the
validity of these signatures and their value to improve
current methods of stage determination, it would be
necessary to perform more validations on independent
cohorts and to verify that they provide stage information
before it is visible by other means in prospective studies.
However, further studies are currently hampered by the
scarcity of large enough RNA-seq datasets with clinical
annotation comparable to TCGA [40].
Conclusions
Our analyses reveal that transcript isoforms hold useful
information to build signatures of stage and clinical out-
come independently of gene expression. Transcript iso-
form signatures appear especially relevant to determine
lymph node invasion and metastasis. We anticipate that
these and similar models may become relevant to under-
stand the progression of tumors beyond DNA and gene
expression alterations, thereby complementing current
molecular approaches in precision cancer medicine.
Methods
Datasets
Processed RNA-seq data from TCGA (https://gdc.nci.nih.-
gov/) was compiled for 12 different tumor types: BRCA,
COAD, HNSC, KICH, KIRC, KIRP, LUAD, LUSC, PRAD,
SKCM, THCA, and OV. The abundance of every tran-
script per sample was calculated in transcripts per million
(TPM) from the transcript-estimated read counts and the
isoform lengths. Genes were defined to be a set of tran-
scripts that overlap in the same genomic locus and strand
and share at least one splice-site (Additional file 1). A gene
TPM was defined as the sum of TPMs for all transcripts
in the gene. The relative abundance of each isoform (PSI),
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was calculated by normalizing the isoform TPM to the
gene TPM. Only genes with a minimum TPM of 0.1 were
considered. Additionally, we used RNA-seq data from the
knockdown of ESR1 and controls in MCF7 cells
(GSE53533) [24], from metastatic melanoma cells
(SKMel147) and melanocytes (GSE68221) [12], and from
the knockdown of MITF and controls using non-
metastatic melanoma cells (Mel505) (GSE61967) [13]. For
each sample, transcript abundances were calculated
with Sailfish [41]. Relative abundances (PSI) of tran-
scripts were calculated as above and the ΔPSI values
between conditions were calculated as the difference
between conditions of the mean values from the rep-
licates. Alternative splicing events and their PSI values
were obtained from [42].
Clinical data
Clinical stage and survival information for patients was
obtained from TGCA. We used the available annotation
for the TNM staging system (www.cancerstaging.org/),
where T followed by a number (1–4) describes the size
of the tumor; N followed by a number (1–3) describes
spread to lymph nodes according to number and dis-
tance; and M followed by 1 or 0 indicates whether the
tumor has metastasized or not, respectively. We also
considered the numbered stage annotation (S), which
goes from 0 to 4, with each number corresponding
approximately to a combination of the TNM numbers.
When any of the stages were subdivided, only the label
of the common class was included (e.g. T1a, T1b, and
T1c were considered as T1). Only patients with defined
stage were used to build the predictive models.
Selection of relevant features
Only isoforms and events with a difference in mean
relative abundance (PSI) of at least 0.1 in absolute value
between the compared patient subgroups were consid-
ered to calculate discriminant isoforms. To obtain
discriminant genes, those with log-fold change of the
mean gene TPM values between the two groups greater
than 2 were considered. Next, a subsampling approach
was used to compare two patient groups through 100
iterations, by extracting the same number of samples
from each group randomly from the input dataset,
using a minimum of 10 samples per group. For pooled
tumor types, the same number of samples per tumor
type was selected at each iteration step. At each
iteration step, three different univariate discriminant
measures were applied (see below), and a permutation
of the group labels was performed and the univariate
measures re-calculated. After 100 iterations, and for
each univariate measure, two distributions of 100
points each are produced for each transcript, corre-
sponding to the observed and expected values.
Transcripts with a positive difference of the means of
the two distributions for all three measures were con-
sidered discriminant and were kept for further analysis.
We applied the following information-based mea-
sures in the subsampling: information gain (IG), gain
ratio (GR), and symmetrical uncertainty (SU). IG is
defined as the mutual information between the group
labels of the training set S and the values of a feature
(or attribute) A, e.g. an isoform: IG(S,A) = MI(S,A) =
H(S) - H(S|A), where H(S) is Shannon’s entropy ac-
cording to the two sample classes and H(S|A) is the
conditional entropy of S with respect to the attribute
A. GR is the mutual information of the group labels
and the attribute, normalized by the entropy contribu-
tion from the proportions of the samples according to
the partitioning by the attribute: GR(S,A) = MI(S,A)/
H(A). Finally, SU provides a symmetric measurement
of feature correlation with the labels and it compen-
sates possible biases from the other two measures:
SU(S,A) = 2 · MI(S,A)/(H(S) + H(A)) [43]. The group la-
bels are the clinical stages (early, late), survival groups
(low, high), or phenotype group (invasive, prolifera-
tive); and the attribute values are the PSI values for
transcript isoforms or alternative splicing events or
the gene TPM values for gene expression analyses.
The continuous PSI or TPM values were discretized as
previously described [44].
Cancer hallmarks and drivers
Enrichment analysis of the 50 cancer hallmarks from
the Molecular Signatures Database v4.0 [45] was
performed with the discriminant isoforms. For each
hallmark, Fisher’s exact test was performed with the
genes with selected isoforms using as controls genes
expressed (TPM >0.1) and with multiple transcripts.
A Benjamini–Hochberg correction was applied and
only cases with a false discovery rate <0.05 were kept.
Known and predicted cancer drivers were obtained as
described in [42].
Transcript signatures
Transcript isoforms that showed a positive difference
between the means of the 100 observed and the 100
randomized values for all three univariate measures
(IG, GR, SU) were analyzed with a Correlation Feature
Selection (CFS) [43]. This selects transcripts with simi-
lar discriminating power but lower redundancy among
them [43], thereby mitigating the problem of overfit-
ting. This was repeated for each comparison between
clinical stages, survival groups, or tumor subtypes.
Using the selected transcript isoforms, an LMT was
built with Rweka [46]. LMTs are classification trees
with logistic regression functions at the leaves. The ac-
curacy of the classifiers was evaluated using the AUC.
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Additionally, we considered the area under the
precision-recall curve (PRC). AUC and PRC take values
between 0 (worst prediction) and 1 (best prediction).
These values were estimated for each classifier through
a tenfold cross-validation, repeated 100 times. The
same approach was used for gene, event, and mixed
models. To apply known gene expression signatures to
our sample groups we used robust Z-scores per gene
and per sample as described before [42]. These values
were then used for the genes in various signatures [21,
26–28]. As before, accuracies were estimated using a
tenfold cross-validation to calculate AUC and PRC
values.
Blind tests
For samples without stage annotation, which were not
used to build the models, we predicted the missing stage
(early/late) or metastatic state, using the corresponding
model for the same tumor type. These newly predicted
samples were then aggregated per clinical class accord-
ing to early and late, or metastatic and non-metastatic,
to test the survival differences between groups. The
blind test was performed using only those tumor types
that already showed significant differences in the sur-
vival between early and late stages for the annotated
samples (Table 2). This analysis was not performed for
T-models, as all samples had a T annotation.
Differential expression analysis
We performed DE analysis for all genes between the
different groups considered in this analysis, using the
same method as described previously [42]. Genes were
considered differentially expressed if the absolute value
of the log2-fold change was greater than 0.5 and
corrected p value < 0.05. Results can be found in
Additional files 5 and 9.
Survival analysis
Survival curves were calculated with the Kaplan–Meier
method and compared between patient subsets using a
Cox proportional hazards regression model [47]. Sur-
vival was measured as date of death minus collection
date for deceased patients and as last contact date minus
collection date for the other patients.
Stromal and immune cell content analysis
To estimate a stromal and immune signature for a
set of samples from a tumor type, we collected a list
of stromal and immune signature genes based on
[18]. We transformed the RNA-Seq by Expectation-
Maximization (RSEM) read counts of these two gene
lists into a gene set score using gene set variation
analysis (GSVA) [48] for each sample. Using the
resulting scores per sample, we then calculated the
Pearson correlations of the stromal and immune
GSVA scores with the transcript isoform PSIs using
all tumor samples, including intermediate stages.
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